Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Status:
Terminated
Trial end date:
2020-02-10
Target enrollment:
Participant gender:
Summary
A double-blinded, placebo-controlled study of Dimethyl fumarate (DMF) in 34 Systemic
Sclerosis-Pulmonary Hypertension (SSc-PAH) patients. The study will determine safety and the
primary outcome variability for DMF in treating SSc-PAH; the primary outcome of clinical
efficacy in this pilot trial will be improvement in 6-minute walk distance (6MWD).